Hesitant to step into this battle, but will dip my toe... First, I own more ATHE (ATH) than any other name in my portfolio. I always consider upside and downside risk, like us all. And I agree with amb500 on the CR. I don't believe, as some have written, that the FDA cares much about what ATH has in the bank - just the trial data, inc. P-values, which were small due to Phase 2 size. Then, maybe the Nfl data, yet to be released in full other than some plasma comments made by Stamler in a webinar. The risk that bothers me the most is - why were there no alternative (e.g. partner/collab) means of financing available? Abbvie ($350B USD market cap) and Biogen as example have had struggles (and some success) - must have been paying attention to our P2. They are chasing the holy grail just as ATH is. Some piece of our future revenue stream (IMO) must have been a more attractive means - to SHs of raising funds - if that alternative were available to us. And why dilute at 1.1 when Stamler could have waited for Nfl results, or other potential catalysts. The dilution, right now, seems unnecessary. More concerning because I've come to conclude that Stamler is a fairly sharp CEO. What, if anything, concerns him about the data (both released or being massaged) that led him to pull the trigger before the market priced our true value into the stock price? Just can't rationalize that decision.
ATH Price at posting:
1.1¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)